<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink">
	
	<front>
		<journal-meta>
			<journal-id journal-id-type="nlm-ta">elife</journal-id>
			<journal-id journal-id-type="hwp">eLife</journal-id>
			<journal-id journal-id-type="publisher-id">eLife</journal-id>
			<journal-title-group>
				<journal-title>eLife</journal-title>
			</journal-title-group>
			<issn pub-type="epub">2050-084X</issn>
			<publisher>
				<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="publisher-id">02445</article-id>
			<article-id pub-id-type="doi">10.7554/eLife.02445</article-id>
			<article-categories>
				<subj-group subj-group-type="display-channel">
					<subject>Research Article</subject>
				</subj-group>
				<subj-group subj-group-type="heading">
					<subject>Genes and Chromosomes</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author" id="author-11207">
					<name>
						<surname>Choi</surname>
						<given-names>Young Eun</given-names>
					</name>
					<aff>
						<addr-line>
							<named-content content-type="department">Department of Radiation Oncology, Division of Genomic Stability and DNA Repair</named-content>
						</addr-line>
						, 
						<institution>Dana-Farber Cancer Institute, Harvard Medical School</institution>
						, 
						<addr-line>
							<named-content content-type="city">Boston</named-content>
						</addr-line>
						, 
						<country>United States</country>
					</aff>
					<xref ref-type="fn" rid="conf1"/>
				</contrib>
				<contrib contrib-type="author" id="author-11211">
					<name>
						<surname>Pan</surname>
						<given-names>Yunfeng</given-names>
					</name>
					<aff>
						<addr-line>
							<named-content content-type="department">Department of Radiation Oncology, Division of Genomic Stability and DNA Repair</named-content>
						</addr-line>
						, 
						<institution>Dana-Farber Cancer Institute, Harvard Medical School</institution>
						, 
						<addr-line>
							<named-content content-type="city">Boston</named-content>
						</addr-line>
						, 
						<country>United States</country>
					</aff>
					<xref ref-type="fn" rid="conf1"/>
				</contrib>
				<contrib contrib-type="author" id="author-11208">
					<name>
						<surname>Park</surname>
						<given-names>Eunmi</given-names>
					</name>
					<aff>
						<addr-line>
							<named-content content-type="department">Department of Radiation Oncology, Division of Genomic Stability and DNA Repair</named-content>
						</addr-line>
						, 
						<institution>Dana-Farber Cancer Institute, Harvard Medical School</institution>
						, 
						<addr-line>
							<named-content content-type="city">Boston</named-content>
						</addr-line>
						, 
						<country>United States</country>
					</aff>
					<xref ref-type="fn" rid="conf1"/>
				</contrib>
				<contrib contrib-type="author" id="author-11209">
					<name>
						<surname>Konstantinopoulos</surname>
						<given-names>Panagiotis</given-names>
					</name>
					<aff>
						<addr-line>
							<named-content content-type="department">Department of Medical Oncology</named-content>
						</addr-line>
						, 
						<institution>Dana-Farber Cancer Institute, Harvard Medical School</institution>
						, 
						<addr-line>
							<named-content content-type="city">Boston</named-content>
						</addr-line>
						, 
						<country>United States</country>
					</aff>
					<xref ref-type="fn" rid="conf1"/>
				</contrib>
				<contrib contrib-type="author" id="author-11212">
					<name>
						<surname>De</surname>
						<given-names>Subhajyoti</given-names>
					</name>
					<aff>
						<addr-line>
							<named-content content-type="department">Department of Medicine</named-content>
						</addr-line>
						, 
						<institution>University of Colorado School of Medicine</institution>
						, 
						<addr-line>
							<named-content content-type="city">Aurora</named-content>
						</addr-line>
						, 
						<country>United States</country>
					</aff>
					<xref ref-type="fn" rid="conf1"/>
				</contrib>
				<contrib contrib-type="author" id="author-11210">
					<name>
						<surname>D'Andrea</surname>
						<given-names>Alan</given-names>
					</name>
					<aff>
						<addr-line>
							<named-content content-type="department">Department of Radiation Oncology,  Division of Genomic Stability and DNA Repair</named-content>
						</addr-line>
						, 
						<institution>Dana-Farber Cancer Institute, Harvard Medical School</institution>
						, 
						<addr-line>
							<named-content content-type="city">Boston</named-content>
						</addr-line>
						, 
						<country>United States</country>
					</aff>
					<xref ref-type="fn" rid="conf1"/>
				</contrib>
				<contrib contrib-type="author" corresp="yes" id="author-11010">
					<name>
						<surname>Chowdhury</surname>
						<given-names>Dipanjan</given-names>
					</name>
					<aff>
						<addr-line>
							<named-content content-type="department">Department of Radiation Oncology, Division of Genomic Stability and DNA Repair</named-content>
						</addr-line>
						, 
						<institution>Dana-Farber Cancer Institute, Harvard Medical School</institution>
						, 
						<addr-line>
							<named-content content-type="city">Boston</named-content>
						</addr-line>
						, 
						<country>United States</country>
						<email>dipanjan_chowdhury@dfci.harvard.edu</email>
					</aff>
					<xref ref-type="fn" rid="conf1"/>
				</contrib>
			</contrib-group>
			<contrib-group content-type="section">
				<contrib contrib-type="editor" id="author-1150">
					<name>
						<surname>Nilsen</surname>
						<given-names>Timothy</given-names>
					</name>
					<role>Reviewing editor</role>
					<aff>
						<institution>Case Western Reserve University</institution>
						, 
						<country>United States</country>
					</aff>
				</contrib>
			</contrib-group>
			<pub-date date-type="pub" publication-format="electronic"><day>30</day><month>04</month><year>2014</year></pub-date><volume>3</volume><elocation-id>e02445</elocation-id>
			<supplementary-material><ext-link xlink:href="elife-02445-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history>
				<date date-type="received">
					<day>02</day>
					<month>02</month>
					<year>2014</year>
				</date>
				<date date-type="accepted">
					<day>29</day>
					<month>04</month>
					<year>2014</year>
				</date>
			</history>
			<permissions>
				<copyright-statement>Copyright Â© 2014, Choi et al</copyright-statement>
				<copyright-year>2014</copyright-year>
				<copyright-holder>Choi et al</copyright-holder>
				<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
					<license-p>
						This article is distributed under the terms of the 
						<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution License</ext-link>
						, which permits unrestricted use and redistribution provided that the original author and source are credited.
					</license-p>
				</license>
			</permissions>
			<abstract>
				<p>Homologous recombination (HR) mediated repair of DNA double-strand break (DSB)s is restricted to the post-replicative phases of the cell cycle. Initiation of HR in the G1 phase blocks non-homologous end joining (NHEJ) impairing DSB repair. Completion of HR in G1 cells can lead to the loss-of-heterozygosity (LOH) which is potentially carcinogenic. We conducted a gain-of-function screen to identify miRNAs that regulate HR-mediated DSB repair, and of these miRNAs, miR-1255b, miR-148b*and miR-193b* specifically suppress the HR-pathway in the G1 phase. These miRNAs target the transcripts of HR factors, BRCA1, BRCA2 and RAD51 and inhibiting miR-1255b, miR-148b*and miR-193b* increases expression of BRCA1/BRCA2/RAD51 specifically in the G1-phase leading to impaired DSB repair. Depletion of CtIP, a BRCA1-associated DNA end resection protein, rescues this phenotype. Furthermore, deletion of miR-1255b, miR-148b*and miR-193b* in independent cohorts of ovarian tumors correlates with significant increase in LOH events/ chromosomal aberrations and BRCA1 expression.</p>
			</abstract>
			<kwd-group kwd-group-type="research-organism">
				<title>Research organism</title>
				<kwd>Human</kwd><kwd>Mouse</kwd></kwd-group>
		</article-meta>
	</front>
	<back>
		<fn-group content-type="competing-interest">
			<title>Competing interest</title>
			<fn fn-type="conflict" id="conf1">
				<p>The authors declare that no competing interests exist.</p>
			</fn>
		</fn-group>
		<fn-group content-type="ethics-information">
			<title>Ethics</title>
			<fn fn-type="other">
				<p>Human subjects: The clinical data from patients was obtained via published sources which include the Cancer Genome Atlas</p>
			</fn>
		</fn-group>
	</back>
</article>